Purpose: Complete macroscopic resection remains the gold standard treatment for retroperitoneal sarcomas (RPS). International guidelines recommend management at specialist sarcoma centres, however an accepted definition is lacking. The aim of this study was to analyse the impact of treating service on surgical and oncological outcomes. Methodology: A retrospective review of patients who underwent resection of primary RPS in Queensland between 2012 and 2022 was performed. Clinico-pathological data was derived from the Queensland Oncology Repository. High-volume sarcoma centre (HVSC) was defined by the presence of a dedicated sarcoma unit, specialised hospital services and a median annual RPS resection volume of greater than five. Results: Of the 144 patients who had a primary RPS resection, 77 (53%) were treated at a HVSC. These patients were more likely to have pre-operative core biopsy (75% vs. 28%, p<0.001), pre-operative MDT presentation (74% vs. 18%, p<0.001), en bloc resection with involved contiguous organs (100% vs. 78%, p<0.001), complete macroscopic resection (99% vs. 87%, p<0.05) and R0 resection (47% vs. 27%, p<0.05). Five-year overall survival was significantly greater for patients treated at a HVSC (73% vs. 63%, p<0.05). Correspondingly, on univariate analysis, treatment outside of a HVSC was associated with a 1.7 fold increase in all cause mortality (CI 1.01-3.01, p<0.05). Conclusion: This series represents the largest population-based analysis of surgical management of RPS in Australia to date. Treatment at a specialist sarcoma centre was associated with better compliance with clinical practice guidelines, optimal oncologic resection and improved 5-year overall survival.